Prophase Labs, INC 8-K filings

ProPhase Labs, Inc. announced it has successfully regained compliance with Nasdaq's audit committee requirements following the appointment of Carolina Abenante, Esq. to its Board of Directors.

ProPhase Labs, Inc. has entered into two senior secured bridge loan agreements totaling $1 million, including a related party transaction with its CEO, to fund working capital and general corporate purposes, with repayment anticipated from future asset sales and accounts receivable collections.

ProPhase Labs, Inc. has entered into two identical $500,000 loan agreements, including one with its CEO, Ted Karkus, at a 10% annual interest rate and a 20% original issue discount, coupled with the issuance of 500,000 unvested warrants.

ProPhase Labs, Inc. has received a 180-day extension from Nasdaq until December 22, 2025, to regain compliance with the minimum $1.00 bid price requirement, following its failure to meet the initial deadline.

ProPhase Labs, Inc. announced the appointment of Carolina Abenante, Esq. as an independent director, effective June 20, 2025, enhancing the company's board and committee expertise.

ProPhase Labs reports Q1 2025 financial results, highlighting strategic shifts towards becoming a lean operating company and anticipating significant liquidity events.

ProPhase Labs reports a challenging 2024 with reduced revenue and a net loss, but outlines strategic initiatives including the sale of its manufacturing division and a focus on BE-Smart commercialization to drive future growth.

ProPhase Labs names Stuart Hollenshead as Chief Operating Officer to spearhead its consumer-facing strategy.

ProPhase Labs reports the departure of current COO Jed Latkin and is in final negotiations to appoint Stuart Hollenshead as the new COO.

ProPhase Labs has entered into a common stock purchase agreement with Keystone Capital Partners, potentially raising up to $7.73 million through the sale of shares.

ProPhase Labs divests its Pharmaloz subsidiaries to JL Projects for approximately $2 million in cash, debt extinguishment, and assumption of liabilities.

ProPhase Labs has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing the company at risk of delisting.

ProPhase Labs announced its Q3 2024 financial results, showcasing a decrease in revenue but highlighting significant progress in strategic initiatives and future growth potential.

ProPhase Labs successfully closed a public offering of 4,795,500 shares of common stock, raising approximately $3.45 million before expenses.

ProPhase Labs plans to sell shares of its common stock in a public offering to raise capital for working capital and general corporate purposes.

ProPhase Labs has engaged Fruci & Associates II as its new independent registered public accounting firm, effective October 18, 2024, following the resignation of Morison Cogen LLP.

ProPhase Labs has announced that its independent auditor, Morison Cogen LLP, has resigned effective September 30, 2024, due to the firm exiting the PCAOB audit business.

ProPhase Labs received a notice from Nasdaq for non-compliance with audit committee requirements following a director's resignation, triggering a cure period to regain compliance.

ProPhase Labs amended a prior loan agreement, increasing the principal to $10 million, and disclosed $16.1 million in working capital as of June 30, 2024.

ProPhase Labs has entered into an amended agreement for a $10 million unsecured promissory note, replacing a previous $7.6 million note, to support working capital and strategic initiatives.

ProPhase Labs announced its Q2 2024 financial results, highlighting strategic advancements and anticipating significant revenue growth in the latter half of the year.

ProPhase Labs successfully elected its board of directors and ratified its independent auditor at the 2024 Annual Meeting of Stockholders.

ProPhase Labs corrects first quarter earnings per share and share count, while also reporting on strategic advancements including a new AI initiative and progress in its cancer diagnostic test.

ProPhase Labs announced its Q1 2024 financial results, revealing a revenue decrease but highlighting significant advancements in strategic initiatives, including a new AI project and progress in cancer diagnostics.

ProPhase Labs has granted stock options to its newly appointed Chief Operating Officer, Jed A. Latkin, as an inducement for his employment.

ProPhase Labs has agreed to a 60-day standstill period, restricting the company from issuing new shares or debt, or entering into certain financial arrangements without ThinkEquity's consent.

ProPhase Labs reports a significant strategic shift towards genomics and manufacturing, with a focus on whole genome sequencing and lozenge production, despite a decrease in overall revenue due to reduced COVID-19 testing.